By Dave Sebastian

Pfizer Inc. and BioNTech SE said a preclinical study for their BNT162b2 vaccine candidate for Covid-19 demonstrated antiviral effects in mice and non-human primates.

The companies on Wednesday said the vaccine candidate is on track for regulatory review as early as October. If they obtain approval, they said they could supply up to 100 million doses by the end of 2020 and about 1.3 billion doses by the end of 2021.

"They have enabled us to advance BNT162b2 into Phase 3 evaluation," BioNTech Chief Executive Ugur Sahin said of the preclinical data.

The companies immunized rhesus macaques with the candidate, which prevented lung infection among all coronavirus-challenged rhesus macaques in the study, the companies said. They said they also didn't detect viral RNA in the coronavirus-challenged rhesus macaques within three days after the infection.

Pfizer and BioNTech earlier said they proposed to supply 200 million doses of their coronavirus vaccine candidate to the European Union, with deliveries starting by the end of this year.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

September 09, 2020 08:25 ET (12:25 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pfizer Charts.